High content screening, also known as cellomics, is used in drug discovery and biological research to identify substances such as peptides, small molecules, or RNAi altering the cell phenotype in the desired manner. In addition, high content screening helps evaluate multiple morphological and biochemical parameters in intact biological systems. This type of screening is conducted in the cells that involve the analysis of components of cells or of whole cells with the readout of several parameters done simultaneously. New drugs can be found using the screens of thousands of molecules. Beyond drug discovery, high content screening can be used to study how genes work.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.
With COVID-19 the supply chain of raw materials required to manufacture high content screening products has been disrupted in many countries. In addition, the market growth of high content screening products is declining, as manufacturers of these devices have slowed down their production due to the pandemic. Therefore, COVID 19 is expected to have a significant impact on the high content screening products market.
Top Impacting Factors
The major factor contributing to the growth of the high content screening products market is increase in funding in the field of cellular research and technological advancements in the design of high content screening systems.
Many conventional methods of drug toxicity studies require the screening of large libraries to search potential drug candidates. This method is highly time and resource-consuming. Hence, many pharmaceutical companies are adopting high content screening solutions to test potential drug toxicity, as the method reduces the time required for testing.
Increase in the number of toxicity studies and the demand for new technologies in cell analysis across the globe are some of the key factors boosting the growth of the market.
In addition, support from the governments of developed nations for life sciences research and rise in the number of research-based biotechnology companies all over the globe boost the growth of the high content screening products market.
However, maintenance costs and the total cost of ownership of high content screening products are considerably high, which impede the growth of the high content screening products market.
Key Market Trends
The instruments segment of the high content screening products market contributed to a large share, owing to advancements in the automation of high content screening instruments.
The software segment of the market is anticipated to register high growth during the forecast period, due to advancements in data analysis, image acquisition, and storage capabilities of high content screening products software.
North America dominates the high content screening products market, owing to high research and development expenditure in high content screening products and the presence of major pharmaceutical players in this region.
The Asia-Pacific market is expected to register high growth during the forecast period, owing to rise in focus of many multinational companies on emerging markets of the region and increase in research in drug discovery, which often require toxicity studies in which high content screening products help.
Key Benefits of the Report
- This study presents the analytical depiction of the high content screening products industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the High Content Screening Products Report
- Which are the leading players active in the high content screening products market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the high content screening products market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps in the market?
- What are the impacts of COVID-19 on the industry?
- What are high content screening products?
- What are the current and predicted trends of the market?
High Content Screening Products Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Application |
|
 By Region |
|
 Key Market Players | Dickinson and Company, Bio-Rad Laboratories, Inc., Merck Millipore Corporation, Danaher Corporation, Olympus Corporation, GE Healthcare, Sysmex Corporation, Yokogawa Electric Corporation, PerkinElmer Inc., Thermo Fisher Scientific Inc. |
Loading Table Of Content...
